Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Daiichi Sankyo
Federal Trade Commission
Cerilliant
Julphar
Baxter
Cantor Fitzgerald
US Department of Justice
Covington

Generated: October 21, 2017

DrugPatentWatch Database Preview

Schering Company Profile

« Back to Dashboard

What is the competitive landscape for SCHERING, and what generic alternatives to SCHERING drugs are available?

SCHERING has one hundred and two approved drugs.

There are nine US patents protecting SCHERING drugs on SCHERING drugs in the past three years.

There are eighty-three patent family members on SCHERING drugs in thirty-two countries and forty-four supplementary protection certificates in ten countries.

Summary for Applicant: Schering

International Patents:83
US Patents:9
Tradenames:64
Ingredients:56
NDAs:102
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
TRILAFON
perphenazine
SYRUP;ORAL011294-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
NORMODYNE
labetalol hydrochloride
TABLET;ORAL018687-002Aug 1, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Schering
REBETOL
ribavirin
SOLUTION;ORAL021546-001Jul 29, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Schering
NORMOZIDE
hydrochlorothiazide; labetalol hydrochloride
TABLET;ORAL019046-001Apr 6, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
PROVENTIL
albuterol sulfate
TABLET, EXTENDED RELEASE;ORAL019383-001Jul 13, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
TINDAL
acetophenazine maleate
TABLET;ORAL012254-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
PROVENTIL
albuterol sulfate
TABLET;ORAL017853-001May 7, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Schering
NOXAFIL
posaconazole
SUSPENSION;ORAL022003-001Sep 15, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Schering Plough
IMDUR
isosorbide mononitrate
TABLET, EXTENDED RELEASE;ORAL020225-003Mar 30, 1995DISCNYesNo► Subscribe► Subscribe► Subscribe
Schering
ESTINYL
ethinyl estradiol
TABLET;ORAL005292-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
VANCENASE
beclomethasone dipropionate
AEROSOL, METERED;NASAL018521-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Schering
NORMOZIDE
hydrochlorothiazide; labetalol hydrochloride
TABLET;ORAL019046-004Apr 6, 1987► Subscribe► Subscribe
Schering Plough
LOTRIMIN
clotrimazole
CREAM;TOPICAL017619-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Schering
NORMOZIDE
hydrochlorothiazide; labetalol hydrochloride
TABLET;ORAL019046-003Apr 6, 1987► Subscribe► Subscribe
Schering
EULEXIN
flutamide
CAPSULE;ORAL018554-001Jan 27, 1989► Subscribe► Subscribe
Schering
PAXIPAM
halazepam
TABLET;ORAL017736-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Schering
NORMODYNE
labetalol hydrochloride
TABLET;ORAL018687-001Aug 31, 1987► Subscribe► Subscribe
Schering
NORMODYNE
labetalol hydrochloride
TABLET;ORAL018687-003Aug 1, 1984► Subscribe► Subscribe
Schering
ETRAFON-FORTE
amitriptyline hydrochloride; perphenazine
TABLET;ORAL014713-006Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Schering
ETRAFON 2-25
amitriptyline hydrochloride; perphenazine
TABLET;ORAL014713-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SCHERING drugs

Drugname Dosage Strength Tradename Submissiondate
posaconazole
Injection18 mg/mL, 16.7 mL vials
NOXAFIL
11/24/2015
posaconazole
Delayed-release Tablets100 mg
NOXAFIL
6/16/2014
posaconazole
Oral Suspension40 mg/mL
NOXAFIL
2/28/2011
eptifibatide
Injection0.75 mg/mL, 100 mL vial
INTEGRILIN
6/5/2009
eptifibatide
Injection2 mg/mL, 100 mL vial
INTEGRILIN
12/18/2008
eptifibatide
Injection2 mg/mL, 10 mL vial
INTEGRILIN
9/30/2008

Non-Orange Book Patents for Schering

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,714,490 Tetrahydrofuran antifungals► Subscribe
5,693,626 Tetrahydrofuran antifungals► Subscribe
5,703,236 Tetrahydrofuran antifungals► Subscribe
5,710,154 Tetrahydrofuran antifungals► Subscribe
6,713,481 Crystalline antifungal polymorph► Subscribe
5,703,079 Tetrahydrofuran antifungals► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Schering Drugs

Country Document Number Estimated Expiration
South Korea20030087052► Subscribe
Japan4308902► Subscribe
China1499930► Subscribe
Spain2159623► Subscribe
European Patent Office0773941► Subscribe
World Intellectual Property Organization (WIPO)9638443► Subscribe
Hungary9701690► Subscribe
Colombia4520281► Subscribe
Australia681753► Subscribe
Slovakia82696► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Schering Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
C/GB95/010United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
2006Austria► SubscribePRODUCT NAME: POSACONAZOL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER ESTERS; REGISTRATION NO/DATE: EU/1/05/320/001 EU/1/05/321/001 20051025
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C/GB12/028United Kingdom► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
2006 00002Denmark► Subscribe
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Argus Health
Deloitte
Federal Trade Commission
Moodys
Covington
McKesson
US Department of Justice
Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot